PLATINUM-RESISTANT FALLOPIAN TUBE CANCER
Clinical trials for PLATINUM-RESISTANT FALLOPIAN TUBE CANCER explained in plain language.
Never miss a new study
Get alerted when new PLATINUM-RESISTANT FALLOPIAN TUBE CANCER trials appear
Sign up with your email to follow new studies for PLATINUM-RESISTANT FALLOPIAN TUBE CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for Platinum-Resistant ovarian cancer: ONC201 and paclitaxel combo trial launches
Disease control Recruiting nowThis Phase 2 trial tests whether adding the experimental drug ONC201 to standard chemotherapy (paclitaxel) can help women with ovarian, fallopian tube, or peritoneal cancer that has stopped responding to platinum-based treatments. About 62 participants will receive the combinatio…
Matched conditions: PLATINUM-RESISTANT FALLOPIAN TUBE CANCER
Phase: PHASE2 • Sponsor: Ira Winer • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New hope for ovarian cancer: targeted drug R-DXd enters key trial
Disease control Recruiting nowThis study tests a new drug called raludotatug deruxtecan (R-DXd) in people with ovarian, peritoneal, or fallopian tube cancer that no longer responds to platinum chemotherapy. The drug is designed to target and kill cancer cells while sparing healthy ones. About 860 participants…
Matched conditions: PLATINUM-RESISTANT FALLOPIAN TUBE CANCER
Phase: PHASE2, PHASE3 • Sponsor: Daiichi Sankyo • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC